TLCM
NVLN

Tiger Legatus Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Tiger Legatus Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-450,000
Closed -$4.15M – 17
2017
Q2 		$4.15M Buy
450,000
+2,148
+0.5% +$20.7K 1.69% 11
2017
Q1 		$4.81M Buy
447,852
+127,852
+40% +$1.31M 2.1% 12
2016
Q4 		$2.69M Buy
+320,000
New +$2.83M 1% 15

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tiger Legatus Capital Management's NVLN Position: Q3 2017 in Review

Tiger Legatus Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2017, closing a stake of 450,000 shares — an estimated $4.15M sold.

Tiger Legatus Capital Management first reported a position in NVLN in Q4 2016 and held it in 3 quarters. The position peaked at $4.81M in Q1 2017. 72 funds tracked by Wall St. Rank hold NVLN as of Q3 2017.

  • Tiger Legatus Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2017 after selling out during the quarter.
  • Tiger Legatus Capital Management sold 450,000 Novelion Therapeutics Inc. Common Shares shares in Q3 2017, an estimated $4.15M.
  • Tiger Legatus Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 3 quarters.
  • Tiger Legatus Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $4.81M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2017.

Based on Tiger Legatus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.